Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Anti-BCMA

- PMLiVE

Sanofi, GSK delay COVID-19 vaccine trial after underwhelming results in elderly participants

Phase 2b study has been delayed to February 2021

- PMLiVE

GSK, Medicago launch phase 2/3 clinical trials of plant-derived COVID-19 vaccine

Vaccine candidate yielded positive phase 1 results

- PMLiVE

Exploring the potential of eosinophils

GSK’s Peter Howarth talks about the emerging research that suggests there is a varied role for eosinophils

- PMLiVE

GSK and Vir Biotech expand phase 3 COVID-19 antibody study

Study extends into additional sites after positive safety assessment

- PMLiVE

GSK chief exec ‘optimistic’ COVID-19 vaccine could be available next year

GSK is currently partnering with Sanofi on a COVID-19 vaccine project

- PMLiVE

FDA hands BMS and bluebird bio a priority review for ide-cel

Updated review accepted after refuse-to-file letter was issued in May

- PMLiVE

Sanofi, GSK to launch human trials of COVID-19 vaccine

Vaccine combines Sanofi’s baculovirus expression system and GSK’s AS03 adjuvant

- PMLiVE

Janssen scores another expansion for new Darzalex combination in the US

Myeloma med approved in combination with Amgen's Kyprolis

- PMLiVE

GSK doses first patients in phase 3 meningitis vaccine trial

Clinical programme will test five-in-one vaccine candidate

- PMLiVE

US secures 100 million doses of Sanofi/GSK’s COVID-19 vaccine

Both companies are also in talks with EU for access to candidate

- PMLiVE

UK government and GSK/Sanofi sign COVID-19 vaccine supply deal

UK adds to its arsenal of potential vaccine candidates

- PMLiVE

GSK agrees on 10% equity stake in mRNA specialist CureVac

Equity investment totals £130m with an upfront payment of £104m

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links